Zynerba Pharmaceuticals, Inc. - FORM S-1/A - EX-23.1 - July 23, 2015

Attached files

file filename
S-1/A - S-1/A - Zynerba Pharmaceuticals, Inc.a2225399zs-1a.htm
EX-3.3 - EX-3.3 - Zynerba Pharmaceuticals, Inc.a2225399zex-3_3.htm
EX-1.1 - EX-1.1 - Zynerba Pharmaceuticals, Inc.a2225399zex-1_1.htm
EX-3.5 - EX-3.5 - Zynerba Pharmaceuticals, Inc.a2225399zex-3_5.htm
EX-3.4 - EX-3.4 - Zynerba Pharmaceuticals, Inc.a2225399zex-3_4.htm
EX-5.1 - EX-5.1 - Zynerba Pharmaceuticals, Inc.a2225399zex-5_1.htm
EX-99.5 - EX-99.5 - Zynerba Pharmaceuticals, Inc.a2225399zex-99_5.htm
EX-99.3 - EX-99.3 - Zynerba Pharmaceuticals, Inc.a2225399zex-99_3.htm
EX-99.6 - EX-99.6 - Zynerba Pharmaceuticals, Inc.a2225399zex-99_6.htm
EX-99.2 - EX-99.2 - Zynerba Pharmaceuticals, Inc.a2225399zex-99_2.htm
EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc.a2225399zex-99_1.htm
EX-21.1 - EX-21.1 - Zynerba Pharmaceuticals, Inc.a2225399zex-21_1.htm
EX-99.4 - EX-99.4 - Zynerba Pharmaceuticals, Inc.a2225399zex-99_4.htm
EX-10.20 - EX-10.20 - Zynerba Pharmaceuticals, Inc.a2225399zex-10_20.htm
EX-10.19(B) - EX-10.19(B) - Zynerba Pharmaceuticals, Inc.a2225399zex-10_19b.htm

QuickLinks -- Click here to rapidly navigate through this document

When the recapitalization referred to in Note 2(1) of the Notes to the Financial Statements has been consummated, we will
be in a position to render the following consent:

/s/ KPMG LLP


Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors
Zynerba Pharmaceuticals, Inc.:

We consent to the use of our report included herein and to the reference to our firm under the heading "Experts" in the prospectus.

Philadelphia, Pennsylvania
July 23, 2015



QuickLinks

Consent of Independent Registered Public Accounting Firm

Zynerba Pharmaceuticals, Inc. Reports

Also read